Multiple Sclerosis: all 3,524 studies
Page 35 of 36. Open to participants first (668), then studies with results posted, then the rest; newest registration first within each.
- Biomarkers in Multiple SclerosisCompletedNCT00325988
- Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple SclerosisCompletedNCT00324506Phase 2
- Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple SclerosisCompletedNCT00321568
- Betaseron Pregnancy RegistryCompletedNCT00317564
- A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory DifficultiesCompletedNCT00315367Phase 4
- Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)WithdrawnNCT00313976Phase 3
- Trial of Memantine for Cognitive Impairment in Multiple SclerosisCompletedNCT00300716Phase 2/3
- Combination Therapy of Betaseron-Prograf in Multiple SclerosisStatus unknownNCT00298662Phase 2
- Phase II High-Dose Cyclophosphamide for Multiple SclerosisWithdrawnNCT00296205Phase 2
- A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)CompletedNCT00292266Phase 3
- Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis SubjectsCompletedNCT00292253Phase 3
- Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic PainCompletedNCT00291148Phase 3
- Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow UpStatus unknownNCT00289159
- A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple SclerosisCompletedNCT00288990
- Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis PatientsCompletedNCT00280592Phase 3
- Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple SclerosisCompletedNCT00276341Phase 3
- Open-Label Natalizumab Safety Extension StudyCompletedNCT00276172Phase 3
- Interferon ß-1b Treatment by Cyclical AdministrationCompletedNCT00270816Phase 2/3
- FOCUS Fatigue Outcome in Copaxone USersCompletedNCT00267319Phase 4
- Simvastatin Treatment of Patients With Acute Optic NeuritisStatus unknownNCT00261326Phase 3
- Cannabis for Spasticity in Multiple SclerosisTerminatedNCT00260741Phase 1/2
- A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple SclerosisCompletedNCT00257855Phase 2
- Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple SclerosisCompletedNCT00248378Phase 1/2
- Autologous T Cell Vaccine (TCV) for Multiple SclerosisCompletedNCT00245622Phase 2
- A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple SclerosisStatus unknownNCT00242268Phase 3
- Pilot Test of ACTOS in Multiple Sclerosis: Safety and TolerabilityCompletedNCT00242177Phase 1
- Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple SclerosisCompletedNCT00241254Phase 3
- A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.CompletedNCT00240032Phase 4
- A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® AloneCompletedNCT00240006Phase 4
- A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®CompletedNCT00239993Phase 4
- A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)TerminatedNCT00239655Phase 2
- A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® TherapyCompletedNCT00238654
- Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MSCompletedNCT00232193
- Infections and Autoimmunity: Autobodies Screening in Multiple SclerosisStatus unknownNCT00230204Phase 1
- Cognitive Effects of Immunomodulatory Drugs in MSCompletedNCT00229502
- Study Evaluating CCI-779 in Relapsing Multiple SclerosisCompletedNCT00228397Phase 2
- TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple SclerosisStatus unknownNCT00228228Phase 3
- Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With RelapsesCompletedNCT00228163Phase 2
- Factors That Influence Compliance With Disease-Modifying Therapy in Multiple SclerosisCompletedNCT00223457
- Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple SclerosisCompletedNCT00223301Phase 2/3
- A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.CompletedNCT00220922Phase 4
- Fatigue Treatment Using ProvigilStatus unknownNCT00220506Not applicable
- Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) PatientsStatus unknownNCT00220493Phase 1
- T-Cell Vaccination in Multiple Sclerosis (MS)Status unknownNCT00220428Phase 1/2
- Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple SclerosisTerminatedNCT00219908Phase 2
- A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple SclerosisStatus unknownNCT00217295Phase 2
- Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MSStatus unknownNCT00210301Not applicable
- An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MSCompletedNCT00206648Phase 4
- Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00206635
- Safety and Efficacy Study of Copaxone Administered in Combination With MinocyclineCompletedNCT00203112Phase 2
- Safety and Efficacy Study of Copaxone Administered in Combination With N-AcetylcysteineCompletedNCT00203099Phase 2
- A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple SclerosisCompletedNCT00203086
- A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.CompletedNCT00203073Phase 2
- Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMSTerminatedNCT00202995Phase 4
- A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved DoseCompletedNCT00202982Phase 2
- Use of Cannabinoids in Patients With Multiple SclerosisStatus unknownNCT00202423Phase 2
- Efficacy of Anti-Tubercular Vaccination in Multiple SclerosisCompletedNCT00202410Phase 2/3
- Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar AtaxiaCompletedNCT00202397Phase 2
- Gene Expression in MS Patients Before and During Treatment With Interferon-betaTerminatedNCT00202384
- Multiple Sclerosis Rehabilitation StudyCompletedNCT00202254Not applicable
- Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple SclerosisCompletedNCT00200655Phase 3
- Efficacy of 3,4-DAP in Fatigue Associated With Multiple SclerosisCompletedNCT00190268Phase 3
- Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MSCompletedNCT00168766Phase 4
- Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)CompletedNCT00168714
- Efficacy and Safety of BG00012 in MSCompletedNCT00168701Phase 2
- Improving New Learning and Memory in Multiple SclerosisCompletedNCT00166283Not applicable
- Restoration of Walking in Multiple Sclerosis Using Treadmill Training.CompletedNCT00156676Not applicable
- Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS PatientsStatus unknownNCT00151801Phase 2
- The Efficacy and Safety of Escitalopram for Depression in Multiple SclerosisTerminatedNCT00151294Phase 4
- Study Evaluating Mitoxantrone in Multiple SclerosisTerminatedNCT00146159Phase 3
- EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple SclerosisCompletedNCT00146068Phase 4
- Effects of Spinal Cord Injury on Female Sexual ResponseStatus unknownNCT00142714Not applicable
- Modafinil in Multiple SclerosisCompletedNCT00142402Not applicable
- A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple SclerosisCompletedNCT00139789Phase 3
- Sleep Disorders in Patients With Multiple SclerosisStatus unknownNCT00137904
- EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple SclerosisCompletedNCT00137176Not applicable
- POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple SclerosisStatus unknownNCT00127075Phase 3
- Health Behavior Change in Chronic Disease ManagementCompletedNCT00118547Not applicable
- AVONEX® Combination Trial - "ACT"CompletedNCT00112034Phase 4
- Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple SclerosisCompletedNCT00109161Phase 2
- A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.WithdrawnNCT00104143Phase 2
- Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple SclerosisCompletedNCT00103974Phase 1
- Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) SubjectsWithdrawnNCT00101959Phase 4
- BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) PatientsCompletedNCT00099502Phase 3
- Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple SclerosisCompletedNCT00099307
- Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00097760Phase 2
- Three Months Treatment With SB683699 In Patients With Relapsing Multiple SclerosisCompletedNCT00097331Phase 2
- A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple SclerosisCompletedNCT00097188Phase 2
- Treating Multiple Sclerosis With Sirolimus, an Immune System SuppressorTerminatedNCT00095329Phase 1/2
- The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis PatientsCompletedNCT00094068
- Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)CompletedNCT00086671Phase 2
- Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)CompletedNCT00079495Phase 2
- Safety of RG2077 in Patients With Multiple SclerosisCompletedNCT00076934Phase 1
- Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple SclerosisCompletedNCT00071838Phase 2
- Treatment of Multiple Sclerosis Using Over the Counter InosineCompletedNCT00067327Phase 2
- MR Perfusion Imaging and Hypercapnia (Increased Carbon Dioxide) to Study New Blood Vessel Formation in Multiple SclerosisCompletedNCT00064909
- Improving Memory in Patients With Multiple SclerosisWithdrawnNCT00062972Phase 3
- Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis PatientsCompletedNCT00050232Phase 3
- Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.CompletedNCT00047580Phase 3
- Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple SclerosisCompletedNCT00043264Phase 2